RNA

Total RNA was prepared from cell line WM3743. WM3743 is a primary post chemotherapy melanoma cell line that displays a mesenchymal morphology. This cell line expresses wild type N-RAS, c-KIT and CDK4 genes. WM3743 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3743. WM3743 is a primary post chemotherapy melanoma cell line that displays a mesenchymal morphology. This cell line expresses wild type N-RAS, c-KIT and CDK4 genes. WM3743 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3749. WM3749 is a metastatic human melanoma cell line that displays a mesenchymal and dendritic morphology. This cell line was established from a metastatic tissue site in a 54-year-old female patient. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses PTEN loss of function including homozygous deletion, and is wild type for N-RAS, c-KIT, and CDK4. WM3749 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3749. WM3749 is a metastatic human melanoma cell line that displays a mesenchymal and dendritic morphology. This cell line was established from a metastatic tissue site in a 54-year-old female patient. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses PTEN loss of function including homozygous deletion, and is wild type for N-RAS, c-KIT, and CDK4. WM3749 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3749. WM3749 is a metastatic human melanoma cell line that displays a mesenchymal and dendritic morphology. This cell line was established from a metastatic tissue site in a 54-year-old female patient. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses PTEN loss of function including homozygous deletion, and is wild type for N-RAS, c-KIT, and CDK4. WM3749 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3755. WM3755 is a metastatic human melanoma cell line that displays a mesenchymal morphology. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line expresses wild type N-RAS, c-KIT, and CDK4 genes. WM3755 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3755. WM3755 is a metastatic human melanoma cell line that displays a mesenchymal morphology. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line expresses wild type N-RAS, c-KIT, and CDK4 genes. WM3755 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3755. WM3755 is a metastatic human melanoma cell line that displays a mesenchymal morphology. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line expresses wild type N-RAS, c-KIT, and CDK4 genes. WM3755 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3758. WM3758 is a metastatic human melanoma cell line. This cell line contains a Q61L mutation at position 61 in the N-RAS gene. The Q61L mutation results in an amino acid substitution at position 61 in NRAS, from a glutamine (Q) to a leucine (L). This cell line expresses wild type BRAF, c-KIT, and CDK4 genes. WM3758 cells match with WM3682 and WM3702. These cells produce xenograft tumors when injected into immunocompromised mice.